There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors.
nadian, and European urology societies recommend a 5α-reductase inhibitor (5ARI) as medical therapy for BPH related LUTS. [2] [3] [4] As a medication class, 5ARIs target the 5α-reductase enzyme family, which is responsible for transforming steroid precursors into active hormones. 5 This includes the conversion of testosterone to dihydrotestosterone, which accounts for the use of 5ARIs for androgenic alopecia and BPH. 5 Among BPH patients, 5ARIs reduce prostate volume, LUTS, and future BPH-related complications and surgery. 6, 7 There are 2 equally efficacious 5ARI medications available for the treatment of BPH 8 : finasteride (which inhibits type 2 5α-reductase) and dutasteride (which inhibits both type 1 and type 2 5α-reductase).
The potential adverse neurologic effects of these medications are an emerging area of concern. In 2011 the United States Food and Drug Agency (FDA) received a postmarketing submission suggesting that self-harm and suicide may be associated with finasteride use, and may persist after discontinuation of the medication. 9 Health Canada recently identified similar concerns. 10 An analysis of the FDA Adverse Event Reporting System found a disproportionately high rate of suicidal ideation reported among men taking finasteride for alopecia. 11 Postmarketing experience resulted in the addition of depression to the 5ARI product monographs. Two prior clinical studies 12, 13 (a secondary analysis of a randomized trial and a cross-sectional study of patients with BPH) suggested there is an increased risk of depression associated with 5ARI use. There is ancillary evidence supporting a potential relationship between 5ARIs and suicidality or depression. First, 5α-reductase is responsible for the production of several neuroactive steroids. 5, 14 Second, testosterone and dihydrotestosterone modulate the neuroendocrine stress response and are inversely related to depression indices. [15] [16] [17] [18] Third, levels of the neurosteroid allopregnanolone (produced by 5α-reductase) are lower among men with depression. 19, 20 Finally, patients with clinical depression have lower levels of type I 5α-reductase in the prefrontal cortex.
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To date, very little research has assessed the potential risks of suicidality and depression from 5ARI medications, despite concerns from regulatory agencies and plausible underlying biologic mechanisms. Our objective was to conduct a population-based retrospective study among older men to assess for a potential relationship between 5ARI use and suicide, selfharm, and depression.
Methods

Design and Setting
We conducted a retrospective, matched-cohort study using existing population-based data from the province of Ontario in Canada. Patient-level data was linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences. A deterministic, patient-level record linkage process was used. Ontario is Canada's largest province (population of 12.9 million people at study midpoint) and the entire population has access to a single health care system. Universal medication coverage is provided for those 65 years or older. This study was approved by the institutional review board at Sunnybrook Health Sciences Centre, Toronto, Ontario, and individual patient consent was not required. The study protocol is included in Supplement 1. Study reporting follows the STROBE/RECORD guidelines for observational studies using routinely collected data (eTable 1 in Supplement 2). 21 
Data Sources
We used several administrative data sources for this study: (1) Registered Persons Database (containing vital statistics), 22 (2) Ontario Drug Benefit database (containing all prescription drug use for Ontarians older than 65 years), 23 
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Our study variables were complete, aside from less than 0.4% missing data for socioeconomic status and rurality (these patients were retained for analysis).
Patient Population
Using the unique drug identification numbers in the Ontario Drug Benefit Database (which has greater than 99% accuracy in prior validation studies) 23 we identified a cohort of men 66 years or older who filled their first prescription for finasteride or dutasteride between January 1, 2003 and December 30, 2013 (exposed men). The prescription fill date was considered the index date for the patient, and the beginning of the observation period. All remaining men in the province of Ontario during the study period (unexposed men) were assigned a random index date based on the distribution of index dates among the exposed men. Within both groups,
Study Outcomes
We prespecified suicide as our primary outcome. Our a priori hypothesis was that suicide would be significantly higher among men exposed to 5ARIs. All cases of unnatural death in Ontario are investigated by a coroner (who is a licensed physician); deaths with clear evidence of suicidal intent 29 are registered as a suicide on the death certificate by the coroner and entered in the Ontario Registrar General-Death database. There is good inter-rater agreement among Ontario coroners for relevant mechanisms of suicide. 30 Our secondary outcomes were self-harm, and incident depression (determined using a validated definition). 31 Self-harm included both emergency department visits for a suicide attempt or parasuicide behavior, and psychiatric hospital admission for recent self-harm or thoughts of self-harm. To identify incident cases of depression, patients with an existing history of depression in the 5 years prior to the index date were excluded for the analysis of this outcome. Details of the data sources, diagnostic codes, and validity of these outcomes are presented in eTable 4 in Supplement 2.
We observed patients for our study outcomes during an at risk period, which was defined as continuous medication usage plus 12 months. Continuous usage started on the day the prescription was filled, and continued for the prescription duration; it was extended for the duration of each follow-up prescription that was filled within 1.5 × the number of days of previous prescription supply. 32 The 12-month post-5ARI period was included owing to the possible persistence of symptoms after the discontinuation of the 5ARI medication. 33, 34 Patients were allowed to switch among 5ARI medications during this at risk period, and on discontinuation of the 5ARI the patient was not reentered in the cohort if they restarted a 5ARI in the future.
Statistical Analysis
Baseline characteristics were compared using standardized differences (SD); an SD greater than 10% was considered a potentially important difference. 35 We used greedy matching (1:1 without replacement) and a caliper of 0.2 standard deviations of the logit of the propensity score.
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Our primary analysis was completed using SAS statistical software (version 9.4, SAS institute). Stratified Cox proportional hazards models were used to account for matching and to censor matched pairs based on the end of the at risk period, or when either member of the pair reached a specified outcome, died, emigrated from the province, or reached the end of the study period (December 31, 2013). The Cox proportional hazards model assumption of proportionality was assessed statistically using a time-dependent covariate, and graphically using Schoenfeld residuals. When proportionality was violated, the model was stratified based on fixed time periods after the index date so that proportionality was restored. Hazard ratios (HRs) and 95% CIs are reported (and the SAS program and output for the primary analysis is included in the eAppendix in Supplement 2), as well as absolute risk. Secondary outcomes were assessed using similar methodology. Three preplanned secondary analyses were conducted. First, we included probable suicide cases in the primary outcome definition (eTable 4 in Supplement 2). Second, 3 potential effect modifiers were assessed (prior depression, prior selfharm, and recent antidepressant usage). Finally, results were stratified by type of 5ARI. The statistical significance of the latter 2 secondary analyses was assessed by adding an interaction term in the model. Two posthoc analyses were performed: outcome models were repeated after matched pairs with a history of prostate cancer (a potential confounder) 37 were excluded, and a competing risk model (using Fine and Gray's method) 38 for nonsuicide mortality was used for our primary and secondary outcomes. For all analyses, we considered 2-tailed P values less than .05 statistically significant.
Results
Cohort selection is presented in eFigure 1 in Supplement 2. After matching we retained 93 197 pairs. Baseline characteristics of the matched exposed and unexposed men that are particularly relevant to our study are presented in Table 1 (complete covariates are presented in eTable 5 in Supplement 2). Acknowledged risk factors for suicide in the elderly, 39, 40 such as mental illness, chronic medical conditions (seizure, neurologic disease, cancer), depression, substance abuse, and prior self-harm episodes were very well balanced between cohorts, and no standardized differences greater than 8% persisted in our final matched cohort for any of the covariates. The index 5ARI was dutasteride for 48 505 (52.0%), and finasteride for 44 692 (48.0%) of men. Dosage, duration of use ,and index prescriber specialty are described in eTable 6 in Supplement 2. The absolute risk of suicide was very low in both exposed and unexposed men (0.04%), and there was no significantly increased HR among men exposed to 5ARI medications (HR, Of the men with self-harm during the study period, 6.9% (9/130) unexposed and 5.9% (10/169) exposed men later died of suicide during our defined at risk period. In our secondary analysis, the potential effect modifiers did not have a significant statistical interaction with our primary outcome of suicide (prior history of depression, P = .32; active depression, P = .56) (eTable 7 in Supplement 2). The prior self-harm subgroup was too small to fit to a statistical model. Stratification of our primary and secondary outcomes by initial type of 5ARI did not reveal any significant differences in the primary or secondary outcomes (Table 3) . Posthoc, the model excluding men with a prior history of prostate cancer (eTable 8 in Supplement 2), and the model accounting for the competing risk of nonsuicide mortality (eTable 9 in Supplement 2) both had similar results to our primary analysis of suicide, self-harm and depression.
Discussion
We conducted a population-based retrospective cohort study of approximately 186 000 men ages 66 years or older to assess for concerning psychiatric problems potentially associated with 5ARIs. We did not demonstrate a significant increase in the risk of suicide among older men using 5ARIs for BPH, and prior depression or antidepressant use did not modify this result. The rate of suicide among men exposed to 5ARIs, and similar men not exposed to 5ARIs was approximately 15 of 100 000 person years in both groups (in keeping with a yearly suicide rate of 19 of 100 000 Ontario males ages 60 or older). 41 However, we did demonstrate a significantly increased risk of self-harm (for the initial 18 months after initiation of a 5ARI), and new diagnoses of depression (throughout follow-up) among men exposed to 5ARI medications. The initial increased risk, which attenuates for both outcomes after 18 months, is in keeping with an acute change associated with the initiation of a 5ARI. These significant differences were consistent among both the finasteride and dutasteride users. Depression in elderly persons is associated with reduced functioning and quality of life, increased health care utilization, and a chronic and relapsing course. 42 Abbreviations: HR, hazard ratio; NA, not applicable.
a The interaction P value represents whether there is a significant difference in the outcome based on the type of 5ARI.
sought treatment for persistent adverse effects after the discontinuation of finasteride, 1 mg, there were high rates of depression, and suicidal thoughts, although there is an obvious selection bias in these studies, and some of these findings may be explained by preexisting psychiatric problems.
33,34,52
Strengths and Limitations
We used a retrospective, matched-cohort design and measured 96 relevant covariates, of which 44 were included in a propensity score. We carefully considered the validity of our primary and secondary study outcomes (eTable 4 in Supplement 2), and censored patients to limit their risk period to ensure there was a temporal association between our exposure and outcomes. Finally, our exposure was defined using the Ontario Drug Benefit database, which has considerable accuracy. 23 Limitations of our study include the possibility of misclassification of key study variables, and residual confounding. Nondifferential misclassification of our outcomes is likely to have occurred given their measurement characteristics, (and would generally bias our results toward the null).
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The true incidence of suicide was likely underestimated, given the limited sensitivity of coroner records for identifying suicide, and depression can be both overdiagnosed and underdiagnosed in the elderly population. 30, 40, 42, 54 Residual confounding is a consistent limitation of any observational study, and while the propensity score accounts for many defined variables, there are covariates (such as family history of suicide and psychosocial supports) 39,46,55 that were not measured; however, they are unlikely to be differentially distributed based on 5ARI use. Furthermore, surveillance and the propensity for a patient to be diagnosed with self-harm and depression may have been different after the initiation of the 5ARI. It is possible there is a small but significant association between suicide and 5ARI usage which we were unable to detect with our sample size (our 95% CI suggests a true HR between 0.53 and 1.45 is possible). Lower urinary tract symptoms themselves may be related to depression, or may lower a patient's quality of life and therefore lead to depressive symptoms. 56 We tried to adjust for this by matching on a history of depression, and balancing recent use of an α antagonist or overactive bladder medication, and prior BPH diagnosis or transurethral prostate surgery. Finally, medication compliance was not directly measured, although, given a median duration of use of approximately 12 months, it is unlikely that men would be refilling a prescription they were not taking.
Implications
The recognition of depression and self-harm as potential adverse effects of 5ARIs is important given their significant impact. However, the relatively small magnitude of these risks should not dissuade physicians from prescribing these medications in appropriate patients. This research may help physicians counsel patients on the risks of 5ARIs. Discontinuation of the 5ARI may be appropriate in the setting of newonset depression or self-harm after the initiation of a 5ARI.
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The outcomes from this study need to be assessed in younger men using finasteride for alopecia. A foundation dedicated to studying the adverse effects of finasteride speaks to the interest among patients in this research topic.
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Conclusions
The risk of suicide was not significantly elevated in men ages 66 years or older using 5ARIs for BPH, however the risks of selfharm and incident depression were significantly increased, primarily during the first 18 months after the initiation of either finasteride or dutasteride. The absolute increased risk of these 2 outcomes was low, and the potential benefits of 5ARIs in this population likely outweigh these risks for most patients. 
Invited Commentary
The Risk of Suicidality and Depression From 5-α Reductase Inhibitors
Stephen Thielke, MD, MS
The Scottish philosopher David Hume observed a fundamental incompatibility between factual and moral propositions, known as Hume's Law: that facts are not the basis for right and wrong, or, put another way, that "should" cannot be derived from "is." Clinicians constantly face this problem, even if they are unconscious of it: striving do the morally right thing on the basis of factually right knowledge, yet depending ultimately on the patient's and their own ideas of what is Good as a means to establish a goal. Scientific advances may thus complicate moral decision-making. In this issue of JAMA Internal Medicine, the findings reported by Welk et al 1 about mental health effects of 5-α reductase inhibitors (5ARIs) illustrate this dilemma. The authors discovered, using more precise methods than in any previous research, a clear association between 5ARI prescription and some negative mental health outcomes among older men with lower urinary tract symptoms (LUTS). Comparing 5ARI users and carefully matched nonusers, there was no difference in risk of suicide. Risk of self-harm was increased by 17 per 100 000 patient-years, but only during the first 18 months of treatment. Risk of incident depression was increased by 272 per 100 000 patient-years, with a mitigated risk after 18 months. Based on these numbers, clinicians would occasionally encounter patients with depression, and would very rarely encounter cases of self-harm, that could be attributed to 5ARIs.
What ought a clinician to do with these findings? Some options include (1) prescribing other medications for LUTS that are not known to increase risk of depression, (2) giving clear warning to all patients about the possible risks, (3) warning those who have had prior depression about the risks, (4) monitoring carefully for depression during 5ARI use, or (5) doing nothing, insofar as the absolute differences in risk were small and the events rare. Hume's Law posits that the facts about 5ARIs and depression do not in themselves inform what should be done. Instead, to get to "should," one must introduce some conception of the desired outcome: doing no harm, increasing some specific aspect of quality of life, reducing rates of mental illness, maximizing patient autonomy, following treatment guidelines, minimizing polypharmacy, ensuring patient satisfaction, avoiding malpractice, or some other aim. Even perfect knowledge about the mechanisms, risks, and benefits of a treatment will not direct either the clinician or patient toward what they want to accomplish. Because some of these aims conflict with others, there is no way to accomplish them all at once, and a moral decision must be made between them, even if no one acknowledges that this occurred.
A key conundrum is weighing dissimilar hypothetical conditions: potentially worsening mood or self-harm behavior vs potentially improved urinary tract symptoms. Lower urinary tract symptoms and depressive symptoms can have significant effects on health-related quality of life, but in a complex way. Mental health variables seem to mediate the relationship between LUTS and quality of life, 2 so causation is unclear. More problematically, there is no common currency for the utility value of not having depression or LUTS, in real or hypothetical form. "Quality of life," as a measurable construct, is almost always defined by researchers rather than patients, and patients may have other frameworks for characterizing a good life. Even when patient-reported outcomes are assessed, 3 it is unclear if patients and researchers are applying the same standards of desirable and undesirable states or outcomes. This point may seem of purely academic interest, but medication adherence patterns provide striking evidence of its centrality in clinical care. In the current study, during 6 years of follow-up, the median duration of 5ARI use was 1 year (as seen in the supplementary table in the article by Welk et al 1 ). This corresponds with other research about high 5ARI discontinuation rates, 4 as well as adherence rates to other prescribed medications. Although the reasons were not specified, it seems clear that very many patients with LUTS voted with their feet and chose not to continue the medications, despite numerous scientific articles touting their benefits, and professional guidelines recommending their ongoing use. Depression and self-harm would account for but a sliver of the discontinuation, and it seems likely that patients found other reasons to stop. The level of patient concern is evident in a patient foundation established to study adverse effects of one 5ARI. Its website enumerates numerous "life-altering" and "devastating" "sexual, neurological, and physical side effects" in postfinasteride syndrome. 5 Are clinicians under an obligation to mention this possible effect when prescribing finasteride? Are they obligated to discuss research about the apparent benefits of 
UNEXPOSED GROUP
Index Event / Inclusion Criteria FOR UNEXPOSED GROUP Index Event: randomly assigned from Jan 1, 2003 until Dec 31, 2013 based on distribution of the index dates among exposed cohort of index dates from exposed cohort.
Inclusions:
1. All Male Ontario residents 66 years of age who were not included in the initial Project Cohort exposed cohort.
Exclusions (in order) FOR UNEXPOSED GROUP
Step Description For the UNEXPOSED group: date randomly assigned based on exposed group.
MATCHING -Exposed and Unexposed groups
We will use greedy matching with specified caliper width of ± 0.2 x the standard deviation of the logit of the propensity score. We will match without replacement Matching Ratio: We will match 1 Exposed patient with 1 (2 if possible) Unexposed patient(s) on:
• Propensity score (based on significant differences between baselines and 
Primary Analysis Plan
I. Report Cohort Selection STOP here for review to confirm sample size.
II.
Report Baseline Characteristics for exposed and unexposed cohorts. Provide standardized differences between exposed and unexposed. Determine baselines relative to index date.
STOP here to review baselines and identify variables to be included in the propensity score.
Redo baseline characteristics table for Cohort (Exposed & Unexposed Groups) post-matching and provide standardized differences. Determine baselines relative to index date.
STOP here to review matched baselines.
Report the HR and 95% confidence intervals for the risk of outcomes by performing cox regression to evaluate the association between 5ARI exposure and the first occurrence of the outcomes in the matched cohorts (unexposed group will serve as the referent group). Assess model for proportionality. Table 2 Outcome data 15 Cohort study -Report numbers of outcome events or summary measures over time Table 2 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included -9: 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1919, 1920, 1921, 1922, 1923, 1928, 1929 I62, I630, I631, I632, I633, I634, I635, I638, I639, I64, H341, I600,  I601, I602, I603, I604, I605, I606, I607, I609, I61, G450, G451, G452, G453 , G458, G459, H340 ICD-10: F110, F111, F112, F113, F114, F115, F116, F117, F118, F119, F120,  F121, F122, F123, F124, F125, F126, F127, F128, F129, F130, F131, F132,  F133, F134, F135, F136, F137, F138, F139, F140, F141, F142, F143, F144,  F145, F146, F147, F148, F149, F150, F151, F152, F153, F154, F155, F156,  F157, F158, F159, F160, F161, F162, F163, F164, F165, F166, F167, F168, F169, F180, F181, F182, F183, F184, F185, F186, F187, F188, F189, F190 Data sources included CIHI-DAD (inpatient discharge abstracts), CIHI-SDS (same day surgeries), NACRS (National Ambulatory Care Reporting System), OHIP (physician billings and diagnosis descriptions), ODB (universal medication coverage), and OMHRS (Ontario Mental Health Reporting System). CIHI-DAD used ICD-10 (for diagnostic coding) and CCI coding (for interventions) after April 1, 2002, and ICD-9/CCP coding prior to this. Specific ICD 9/10 and CCP/CCI codes, and medication classes used to define hypertension and diabetes are defined above. The presence of any data element was considered evidence of the comorbidity. A look-back window of 5 years prior to index date was used for all conditions, aside from hypertension and diabetes (which used a 6 month look-back period due to the use of medications to define these conditions).
Association between
Substance abuse (excluding alcohol)
CIHI-DAD CIHI-SDS NACRS
eTable 2b. Specific drugs included within each medication class. Approximately 7,400 individual Drug Identification Numbers (DINs) were used to identify relevant brands and doses. A 6 month lookback window relative to the index date was used. Data source was the ODB, which provides universal medication coverage to all people over 65 years of age. Each medication is identified with a unique and permanent DIN. The presence of any medication within the medication class in the 6 months prior to the index date was considered evidence of recent or current medication usage.
eTable 2c. Administrative data definitions used to define medical investigations and procedures. A 1 year lookback window relative to the index date was used. Code: G311, G320, G647, G648, G649, G650, G651, G652, G653,  G654, G655, G656, G657, G658, G659, G660, G661, G682, G683, G684,  G685, G686, G687, G688, G689, Data sources included CIHI-DAD (inpatient discharge abstracts) and OHIP (physician billings). CIHI-DAD used ICD-10 (for diagnostic coding) and CCI coding (for interventions) after April 1, 2002, and ICD-9/CCP coding prior to this. Specific OHIP, ICD 9/10 and CCP/CCI codes are defined above. The presence of any data element within the year prior to the index date was considered evidence of the medical test or intervention. eTable 3. Variables included in the propensity score. Variables were included based on 1) an initial standardized difference >7%, 2) a potentially important relationship with study outcomes, or 3) a standardized difference >10% after initial matching. 5ARIs in our study population are only indicated for the treatment of lower urinary tract symptoms from BPH. They may have also been used to treat gross hematuria in BPH patients, and although they may reduce the risk of prostate cancer 2 , they were not approved, or widely used for this indication. The potential confounders of socioeconomic status, alcoholism, psychiatric diseases and medications, narcotics, electroconvulsive therapy and CT/MRI head were included due to a potential relationship with suicide or depression, although prior to the propensity score adjustment these were well balanced and therefore unlikely to confound our results. Exposed men had a higher level of hospital/emergency room admissions, and family physician visits, which may have led to an increased risk of our secondary outcomes due to the increased health care contact leading to a greater propensity to diagnose depression or detect selfharm if they were not included in the propensity score. Similarly, exposed men tended to have more medical comorbidities, as measured by the John Hopkins ADG score, which is a risk factor for suicide. *Self-harm includes suicide attempts and para-suicide behavior that presents to the emergency room (ICD 10 X60-84), and men with a recent history of suicide attempt/para-suicide behavior that results in admission to a psychiatric hospital (Self-injury attempts It also includes men who are admitted to a psychiatric hospital because of only thoughts of self-harm (Self-injury intent=true, Self-injury considered=true, Self-injury plan=true).
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ORGD (Ontario register general death) contains cause of death for all residents based on death certificates. NACRS (National Ambulatory Care Reporting System, all emergency room visits), OMHRS (Ontario Mental Health Reporting System, all psychiatric hospitalisations after 2005), and CIHI-DAD (Canadian Institute for health informatics inpatient discharge abstracts) are based on data extracted from medical records by trained abstractors, and data quality is maintained though audit-feedback systems. Data on diagnoses are coded using ICD 10. For NACRS, OMHRS, and CIHI-DAD, up to 25 diagnoses can be coded per patient per admission/visit. Data elements have >80% agreement with medical records during reabstraction studies. [1] [2] [3] A prior validation study [4] demonstrated that Ontario coroners had high inter-rater consistency when identifying deaths from hanging and carbon monoxide poisoning as suicide, however were more likely to code over the counter medication overdose, heroin intoxication, or drowning suicides as an undetermined cause of death. Older males in Canada who die from suicide tend to use methods with little equivocation as to intent (firearm, hanging, suffocation). [5] Coroner reports have been used in numerous studies to evaluate suicide rates and risk factors. [6] Validation studies in the United Kingdom assessing the electronic coding accuracy of suicide as a cause of death, and self-harm behavior have suggested that the positive predictive value of suicide coding is 88% (78-94%) and the positive predictive value of self-harm coding is 89% (82 to 95%). [7] The ICD 10 codes used for suicide and self-harm have been used in several prior Ontario-based studies. [8] [9] [10] A systematic review has summarised the results of validation studies for administrative data definitions of depression. [11] Positive predictive values for ICD 10 coding algorithms range from 89.5 to 91.1%, and jurisdiction specific algorithms were recommended. A Canadian study [12] validated the use of physician billing records and hospital discharge abstracts for identifying depression, and this definition was used for our study (with the addition of OMHRS data, which would be expected to improve the specificity of this algorithm further). The algorithm's sensitivity was 77.5%, specificity 93.0%, positive predictive value 91.6%, negative predictive value 80.7%, Kappa 0.71 (95% CI 0.64 to 0.77). Final unexposed cohort n=93,197 eFigure 2. Graph of Schoenfeld residuals for suicide, self-harm, and depression. Significant deviation of the plotted line (shown with 95% confidence intervals) from the straight dotted line at 0 on the y axis indicates a violation of the proportionality assumption. The statistical test for violation of the proportionality assumption (p value of a time varying covariate) is also included.
Medical Investigations and Procedures
A) Suicide (p=0.54, suggesting no significant deviation from proportionality).
5e−03 5e−02 5e−01 5e+00 Time B) Self-harm (p<0.05, suggesting a significant deviation from proportionality).
5e−03 5e−02 5e−01 5e+00 Time C) Depression (p<0.05, suggesting a significant deviation from proportionality). Years post index date
